Select Language
CD28
CD28 Overview
| English Name | T-cell-specific surface glycoprotein CD28 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 24 | Target Synonym | CD28，CD28 Antigen，T-Cell-Specific Surface Glycoprotein CD28，CD28 Antigen (Tp44)，Tp44，CD28 Antigens，CD28 Molecule，T-Cell-Specific Surface Glycoprotein |
| Highest Development Stage | Phase 2 Clinical | ||
| English Name | T-cell-specific surface glycoprotein CD28 |
| Target Synonym | CD28，CD28 Antigen，T-Cell-Specific Surface Glycoprotein CD28，CD28 Antigen (Tp44)，Tp44，CD28 Antigens，CD28 Molecule，T-Cell-Specific Surface Glycoprotein |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 24 |
| Highest Development Stage | Phase 2 Clinical |
CD28 Product List
- Product Category
Protein (9)Antibody (6)Kits (1)
- Product Status
Launched (16)
- Species
Mouse (10)Human / Cynomolgus / Rhesus macaque (5)Rat (1)
- Tag
His Tag (3)Fc Tag & Avi Tag (1)Mouse IgG Fc Tag (1)Fc Tag (2)His Tag & Avi Tag (2)Mouse IgG1 (2)- (5)
- Conjugate
Unconjugated (9)Biotin-labeled (4)- (1)PE Labeled (1)APC Labeled (1)
Total: 16
- 1
- 2
CD28 Background
T-cell-specific surface glycoprotein CD28 is also known as TP44, is a single-pass type I membrane protein which contains one Ig-like V-type (immunoglobulin-like) domain. is one of the molecules expressed on T cells that provide co-stimulatory signals, which are required for T cell activation. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2). When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen presenting cells (APCs). The CD86 expression on antigen presenting cells is constitutive. CD28 is the only B7 receptor constitutively expressed on naive T cells.
CD28 Synonyms
CD28,Tp44
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Nezastomig | REGN-5678 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
| Abatacept (Orban Biotech) | Phase 2 Clinical | Orban Biotech, The National Institute Of Diabetes And Digestive And Kidney Diseases | Diabetes Mellitus, Type 1 | Details | |
| Lulizumab pegol | Lulizumab; BMS-931699 | Phase 2 Clinical | Bristol-Myers Squibb Company | Rejection of renal transplantation; Lupus Vulgaris; Sjogren-Larsson Syndrome | Details |
| Acazicolcept | ALPN-101 | Phase 2 Clinical | Alpine Immune Sciences Inc | Graft vs Host Disease; Autoimmune Diseases; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders; Inflammation | Details |
| FR-104 | FR-104; JNJ-3133; VEL-101 | Phase 2 Clinical | Effimune | Rejection of renal transplantation; Arthritis, Rheumatoid; Postoperative Complications | Details |
| TC-510 | TC-510 | Phase 2 Clinical | Tcr2 Therapeutics Inc | Ovarian Neoplasms; Solid tumours; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Mesothelioma; Cholangiocarcinoma; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| REGN-7945 | REGN7945; REGN-7945 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Multiple Myeloma | Details |
| MDX-2001 | MDX-2001; MDX2001 | Phase 2 Clinical | ModeX Therapeutics Inc | Kidney Neoplasms; Biliary Tract Neoplasms; Head and Neck Neoplasms; Esophageal Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Colonic Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Thyroid Neoplasms; Endometrial Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms | Details |
| REGN-7075 | REGN-7075 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Solid tumours; Carcinoma, Non-Small-Cell Lung | Details |
| REGN-5668 | REGN-5668 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Endometrial Neoplasms | Details |
| ATLCAR.k.CD28 cells (UNC Lineberger Comprehensive Cancer Center) | Phase 1 Clinical | Unc Lineberger Comprehensive Cancer Center | Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma | Details | |
| SAR-442257 | SAR-442257 | Phase 1 Clinical | Sanofi | Neoplasms | Details |
| Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Lymphoma, Non-Hodgkin | Details | |
| SAR-446422 | SAR-446422; SAR446422 | Phase 1 Clinical | Sanofi | Autoimmune Diseases | Details |
| JNJ-1493 | JNJ-1493 | Phase 1 Clinical | Xencor Inc | Hematologic Neoplasms; Lymphoma, B-Cell | Details |
| JNJ-9401 | JNJ-9401 | Phase 1 Clinical | Xencor Inc | Prostatic Neoplasms | Details |
| JNJ-87189401 | JNJ-87189401 | Phase 1 Clinical | Janssen Research & Development Llc | Prostatic Neoplasms | Details |
| REGN5837 | REGN5837; REGN-5837 | Phase 1 Clinical | Regeneron Pharmaceuticals Inc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| CC-312 | CC-312 | Phase 1 Clinical | CytoCares (Shanghai) Inc | Hematologic Neoplasms; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| XmAb-808 | XmAb808 | Phase 1 Clinical | Xencor Inc | Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Ovarian Epithelial; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Prostatic Neoplasms, Castration-Resistant; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| SAR-443216 | SAR-443216 | Phase 1 Clinical | Sanofi | Solid tumours; Stomach Neoplasms; Neoplasms; Breast Neoplasms; Lung Neoplasms | Details |
| CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular | Details | |
| B7-2/GM-CSF cancer gene therapy | CIT | Phase 1 Clinical | Radient | Neoplasms | Details |
| InHeAb-01 | InHeAb-01; bsAB | Clinical | University Hospital Tuebingen | Neoplasms | Details |
Product Reviews
q***g2026-03-23
0People Likeechnical Serviceechnical Serviceechnical Serviceechnical Serviceechnical Serviceechnical Serviceechnical Service- q***g2026-03-23 0People Like测试是否发放积分测试是否发放积分测试是否发放积分测试是否发放积分测试是否发放积分
q***g2026-02-11 0People LikeProduct QualityProduct QualityProduct QualityProduct QualityProduct QualityProduct QualityProduct QualityProduct QualityProduct QualityProduct QualityProduct QualityProduct QualityProduct QualityProduct Quality
Load More
- Overview
- Product List
- Product Reviews
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland